The effects of anabolic androgenic steroids on serum ubiquinone and dolichol levels among steroid abusers
| Autor: | Jaakko-Juhan Himberg, Tuomo Karila, Timo Seppälä, Kalle Jokelainen, Reijo Laaksonen |
|---|---|
| Rok vydání: | 1996 |
| Předmět: |
Adult
Male medicine.medical_specialty Arteriosclerosis Substance-Related Disorders Ubiquinone medicine.drug_class Endocrinology Diabetes and Metabolism medicine.medical_treatment Mevalonic Acid 030209 endocrinology & metabolism Steroid 03 medical and health sciences chemistry.chemical_compound Anabolic Agents 0302 clinical medicine Endocrinology Dolichol Dolichols Internal medicine medicine Humans 030304 developmental biology 0303 health sciences Chemistry Cholesterol Cholesterol HDL Cholesterol LDL Androgen Anabolic-Androgenic Steroids 3. Good health Toxicity lipids (amino acids peptides and proteins) Mevalonate pathway Lipoprotein |
| Zdroj: | Metabolism. 45:844-847 |
| ISSN: | 0026-0495 |
| Popis: | We measured serum ubiquinone and dolichol concentrations in 13 men while they abused anabolic androgenic steroids (AAS) and during the following withdrawal period. Serum total, high-density lipoprotein (HDL), and low-density lipoprotein (LDL) cholesterol and triglycerides were also determined. AAS administration increased serum ubiquinone by 68% (P < .001) and decreased serum dolichol by 30% (P < .002). Both nonsterol isoprenoid levels in plasma correlated with the AAS dose, ubiquinone positively (P < .001) and dolichol negatively (P < .002). When the subjects were taking steroids, the ubiquinone to LDL ratio was 42% higher than during the withdrawal period. In conclusion, our study suggests that AAS have an influence on the by-products of the mevalonate pathway. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect